1 00:00:02,520 --> 00:00:07,360 Speaker 1: Bloomberg Audio Studios, podcasts, radio News. 2 00:00:08,560 --> 00:00:12,440 Speaker 2: The Stock Movers Report, your roundup of companies making moves 3 00:00:12,480 --> 00:00:16,160 Speaker 2: in the stock market. Harnessing the power of Bloomberg Data. 4 00:00:16,480 --> 00:00:18,520 Speaker 1: Let's take a look at some stocks on the move today. 5 00:00:18,560 --> 00:00:21,680 Speaker 1: I'm Nathan Hager, joined by Bloomberg's Dan Curtis on a 6 00:00:21,720 --> 00:00:24,880 Speaker 1: morning with a lot going on in the pharma space, 7 00:00:25,120 --> 00:00:30,280 Speaker 1: including the latest in the obesity drug wars, another setback 8 00:00:30,640 --> 00:00:33,960 Speaker 1: for Nova nordis. Good morning Dan, Good morning Nathan. 9 00:00:34,000 --> 00:00:36,240 Speaker 3: That's right. I'm not sure what's falling harder this morning. 10 00:00:36,280 --> 00:00:40,000 Speaker 3: Novo notice shares or the snow but ticker Envo for 11 00:00:40,040 --> 00:00:43,600 Speaker 3: the usadrs. Those shares are down fifteen percent as the 12 00:00:43,600 --> 00:00:48,080 Speaker 3: pharmaceuticals next gen obcit shot Kagrissima, is less effective than 13 00:00:48,120 --> 00:00:51,720 Speaker 3: Eli Lilly's rival in a trial. So this morning Novo 14 00:00:51,800 --> 00:00:55,160 Speaker 3: came out saying that in its trial there is twenty 15 00:00:55,320 --> 00:00:57,800 Speaker 3: percent weight loss after about a year and a half. 16 00:00:57,840 --> 00:01:02,080 Speaker 3: That's versus nearly twenty four percent weight loss from Eli Lily. 17 00:01:02,560 --> 00:01:05,640 Speaker 3: Kigrosima is a key piece for novo strategy that's ahead 18 00:01:05,680 --> 00:01:08,120 Speaker 3: of the patent xpree for its headline with go vi 19 00:01:08,319 --> 00:01:11,680 Speaker 3: ozembic weight loss drugs and the Wall Straight Street base 20 00:01:11,800 --> 00:01:14,480 Speaker 3: case going into this is that Novo's drug wouldn't be 21 00:01:14,600 --> 00:01:17,479 Speaker 3: worse than Eli Lilly. That's according to a UBS note. 22 00:01:17,520 --> 00:01:21,240 Speaker 3: So this taking markets off guard, those shares down fifteen percent, 23 00:01:21,360 --> 00:01:24,280 Speaker 3: Eli Lilly the competitor, getting a three percent pop in 24 00:01:24,400 --> 00:01:25,039 Speaker 3: pre market. 25 00:01:25,440 --> 00:01:27,839 Speaker 1: And we have some deal news in the pharma space. 26 00:01:27,920 --> 00:01:30,559 Speaker 1: Gilead Sciences on the hunt this morning. 27 00:01:31,000 --> 00:01:33,560 Speaker 3: That's right, Gilead has announced it's going to buy Our 28 00:01:33,640 --> 00:01:36,760 Speaker 3: Selects for one hundred and fifteen dollars in cash plus 29 00:01:36,760 --> 00:01:39,120 Speaker 3: a contingent value right of five dollars a share, so 30 00:01:39,280 --> 00:01:41,840 Speaker 3: up to one hundred and twenty dollars a share. That's 31 00:01:41,880 --> 00:01:45,039 Speaker 3: popping Our select shares up seventy eight percent in the 32 00:01:45,080 --> 00:01:47,520 Speaker 3: pre market. They're trading at one fourteen, so not too 33 00:01:47,560 --> 00:01:50,960 Speaker 3: far off what Gilead has offered. Our Selects is a 34 00:01:51,000 --> 00:01:55,320 Speaker 3: biotech company that focuses on immunotherapy patients with cancers, and 35 00:01:55,480 --> 00:01:59,720 Speaker 3: Our Selects Gilead already have a collaboration on Our Selection's 36 00:01:59,800 --> 00:02:03,400 Speaker 3: lead pipeline candidate. Gilead already owns eleven point five percent 37 00:02:03,400 --> 00:02:06,560 Speaker 3: of out standing our Slix's stock, and Gilead has been 38 00:02:06,560 --> 00:02:09,200 Speaker 3: looking for deals to supplement its core portfolio, so it's 39 00:02:09,240 --> 00:02:12,119 Speaker 3: buying about ninety percent of the other stock that's out. 40 00:02:12,680 --> 00:02:14,520 Speaker 3: Big lift in the pre market. 41 00:02:14,360 --> 00:02:16,799 Speaker 1: And Mark's making a bit of deal news in sort 42 00:02:16,840 --> 00:02:19,000 Speaker 1: of the opposite direction this morning. 43 00:02:19,280 --> 00:02:22,600 Speaker 3: That's right, So Mark taker m Marque is up about 44 00:02:22,639 --> 00:02:25,040 Speaker 3: one percent in pre market. The company is splitting its 45 00:02:25,120 --> 00:02:27,800 Speaker 3: human health business into two units. That's on collegey unit 46 00:02:28,000 --> 00:02:32,320 Speaker 3: and then a specialty pharma infectious unit. The company says 47 00:02:32,360 --> 00:02:35,280 Speaker 3: that's a response to a more diversified pipeline that it's 48 00:02:35,320 --> 00:02:38,480 Speaker 3: pushing out. It currently has eighty phase three studies. The 49 00:02:38,520 --> 00:02:43,080 Speaker 3: oncology unit is a beast within Market's contributed over thirty 50 00:02:43,080 --> 00:02:45,760 Speaker 3: five of the fifty eight billion dollars in sales last year, 51 00:02:45,880 --> 00:02:47,560 Speaker 3: so this is allowing it to focus more on the 52 00:02:47,639 --> 00:02:50,280 Speaker 3: encology unit and specially and separate out kind of all 53 00:02:50,320 --> 00:02:53,919 Speaker 3: the other drive drivers within that human business. Again, those 54 00:02:53,919 --> 00:02:55,720 Speaker 3: shares up about one percent in pre. 55 00:02:56,040 --> 00:02:58,840 Speaker 1: And while we wind down earning season, we got some 56 00:02:58,960 --> 00:03:01,400 Speaker 1: results this morning from Domino's Pizza Dan. 57 00:03:01,840 --> 00:03:04,760 Speaker 2: What did they deliver? Hahaha? 58 00:03:05,080 --> 00:03:08,720 Speaker 3: They delivered a beat. So if you if you ordered that, 59 00:03:08,840 --> 00:03:12,640 Speaker 3: then congratulations, it's been delivered this morning. Fourth quarter revenue 60 00:03:12,639 --> 00:03:16,919 Speaker 3: same store sales growth those both beat estimates. US same 61 00:03:16,960 --> 00:03:19,480 Speaker 3: store sales, so that's comparable growth came in at three 62 00:03:19,520 --> 00:03:22,960 Speaker 3: point seven percent. That was above estimates. International lag at 63 00:03:23,040 --> 00:03:26,760 Speaker 3: zero point seven percent, but enough to drive the revenue beat. However, 64 00:03:26,880 --> 00:03:29,880 Speaker 3: the company's margins did shrink, with earnings coming in just 65 00:03:29,960 --> 00:03:33,040 Speaker 3: shy of what Wall Street was expecting. Domino cited higher 66 00:03:33,040 --> 00:03:37,240 Speaker 3: insurance costs, higher labor rates, and inflation, something we've been 67 00:03:37,240 --> 00:03:41,320 Speaker 3: talking about NonStop. Domino's Pizza. Another tailwind is also increasing 68 00:03:41,320 --> 00:03:44,160 Speaker 3: its dividend by fifteen percent to nearly two dollars a share, 69 00:03:44,280 --> 00:03:45,880 Speaker 3: that was higher than the Bloomberg projection. 70 00:03:46,880 --> 00:03:50,920 Speaker 2: This stock Movers report from Bloomberg Radio. Check back with 71 00:03:51,000 --> 00:03:53,560 Speaker 2: us throughout the day for the latest roundup of companies 72 00:03:53,640 --> 00:03:56,720 Speaker 2: making news on Wall Street and for the latest market 73 00:03:56,760 --> 00:04:01,240 Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube, 74 00:04:01,320 --> 00:04:04,840 Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with 75 00:04:04,880 --> 00:04:06,360 Speaker 2: the Bloomberg Business app.